New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 1000 [iu] equivalent to 90 µg;   - injection with diluent - 1000 iu - active: moroctocog alfa 1000 [iu] equivalent to 90 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 2000 [iu] equivalent to 180 µg;   - injection with diluent - 2000 iu - active: moroctocog alfa 2000 [iu] equivalent to 180 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 250 [iu] equivalent to 23 µg;   - injection with diluent - 250 iu - active: moroctocog alfa 250 [iu] equivalent to 23 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 500 [iu] equivalent to 45 µg;   - injection with diluent - 500 iu - active: moroctocog alfa 500 [iu] equivalent to 45 µg   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - moroctocog alfa 3000 [iu];   - injection with diluent - 3000 iu - active: moroctocog alfa 3000 [iu]   excipient: calcium chloride dihydrate histidine polysorbate 80 sodium chloride sucrose sodium chloride water for injection - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - solution for infusion - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin - solution for infusion - moxifloxacin 400 mg / 250 ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 2000 iu - diluent, not applicable - excipient ingredients: sodium chloride; water for injections - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.